• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Eli Lilly’s Global Vault CRM Rollout At Veeva Systems (VEEV) Has Changed Its Investment Story

    Simply Wall St·08/20/2026 02:27:15
    Listen to the news
    • Earlier this month, Eli Lilly and Company committed to deploy Veeva Vault CRM globally as part of Veeva’s Vault CRM Suite supporting agentic commercial workflows.
    • This global rollout by a major pharmaceutical company highlights growing interest in AI-enabled commercial tools like Veeva’s Agentic Call Report to help generate commercial evidence.
    • We’ll now examine how Eli Lilly’s global Vault CRM commitment could influence Veeva’s investment narrative, especially around AI‑driven commercial execution.

    This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.

    Veeva Systems Investment Narrative Recap

    To own Veeva, you generally need to believe that life sciences will keep standardizing on its cloud platforms and increasingly adopt embedded AI agents across clinical and commercial workflows. Eli Lilly’s global Vault CRM rollout reinforces the AI‑driven execution catalyst in the near term, while also highlighting a key risk: heavier dependence on a concentrated group of large pharma customers whose future budgets and bargaining power could materially influence Veeva’s pricing and growth profile.

    Among recent developments, Veeva’s June 2026 guidance raise for fiscal 2027 to US$3,635 million to US$3,645 million in revenue stands out. That update, together with accelerating Vault CRM commitments from companies like Merck KGaA and Teva, frames Eli Lilly’s global rollout as part of a broader shift toward Veeva’s AI‑enabled suites, which could matter for how investors think about both the CRM transition catalyst and concentration risk in the commercial business.

    Yet beneath the optimism around Eli Lilly, investors should still pay close attention to the growing concentration of revenue among top pharma accounts and...

    Read the full narrative on Veeva Systems (it's free!)

    Veeva Systems' narrative projects $4.7 billion revenue and $1.4 billion earnings by 2029. This requires 12.4% yearly revenue growth and about a $0.5 billion earnings increase from $941.7 million today.

    Uncover how Veeva Systems' forecasts yield a $245.48 fair value, in line with its current price.

    Exploring Other Perspectives

    VEEV 1-Year Stock Price Chart
    VEEV 1-Year Stock Price Chart

    Some of the lowest ranked analysts were expecting only about US$4.5 billion in revenue and US$1.3 billion in earnings by 2029, so compared with today’s AI and Vault CRM momentum, their more cautious view on how quickly Veeva’s AI agents and broader cloud adoption might translate into durable financial outcomes offers you a useful contrast to explore.

    Explore 12 other fair value estimates on Veeva Systems - why the stock might be worth 34% less than the current price!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your Veeva Systems research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free Veeva Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Veeva Systems' overall financial health at a glance.

    Curious About Other Options?

    Every day counts. These free picks are already gaining attention. See them before the crowd does:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.